Evidence map›Paper›PMID 37888115›Full record

ArticleJournal of personalized medicine2023

Sox2 and βIII-Tubulin as Biomarkers of Drug Resistance in Poorly Differentiated Sinonasal Carcinomas.

Luis López, Laura Fernández-Vañes, Virginia N Cabal, Rocío García-Marín, Laura Suárez-Fernández, Helena Codina-Martínez, Sara L Lorenzo-Guerra, Blanca Vivanco, Verónica Blanco-Lorenzo, José L Llorente and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Update on olfactory neuroblastoma.Virchows Archiv : an international journal of pathology · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Luis LópezDepartment of Otolaryngology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.ORCID 0000-0002-9720-2252
Laura Fernández-VañesDepartment of Otolaryngology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Virginia N CabalDepartment of Head and Neck Cancer, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-4490-5747
Rocío García-MarínDepartment of Head and Neck Cancer, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0003-0331-2002
Laura Suárez-FernándezDepartment of Head and Neck Cancer, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0009-0004-0835-7546
Helena Codina-MartínezDepartment of Head and Neck Cancer, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Sara L Lorenzo-GuerraDepartment of Head and Neck Cancer, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-9169-0267
Blanca VivancoDepartment of Pathology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Verónica Blanco-LorenzoDepartment of Pathology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
José L LlorenteDepartment of Otolaryngology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Fernando LópezDepartment of Otolaryngology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.ORCID 0000-0001-7019-9746
Mario A HermsenDepartment of Head and Neck Cancer, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-5959-6289
Hospital Universitario Central de Asturias · ESInstituto de Investigación Sanitaria del Principado de Asturias · ES

Funding

Centro de Investigación Biomédica en Red de Cáncer CB16/12/00390Instituto de Salud Carlos III FI20/00137Instituto de Salud Carlos III PI19/00191Instituto de Salud Carlos III PI20/00383Instituto de Salud Carlos III PI22/00506
6 · The paper itself

Abstract

Poorly differentiated sinonasal carcinomas (PDCs) are tumors that have a poor prognosis despite advances in classical treatment. Predictive and prognostic markers and new personalized treatments could improve the oncological outcomes of patients. In this study, we analyzed SOX2 and βIII-tubulin as biomarkers that could have prognostic and therapeutic impacts on these tumors. The cohort included 57 cases of PDCs: 36 sinonasal undifferentiated carcinoma (SNUC) cases, 13 olfactory neuroblastoma (ONB) cases, and 8 sinonasal neuroendocrine carcinoma (SNEC) cases. Clinical follow-up data were available for 26 of these cases. Sox2 expression was detected using immunohistochemistry in 6 (75%) SNEC cases, 19 (53%) SNUC cases, and 6 (46%) ONB cases. The absence of Sox2 staining correlated with a higher rate of recurrence (

Indexed as

olfactory neuroblastoma (ONB)poorly differentiated sinonasal carcinomas (PDCs)prognostic biomarkersinonasal neuroendocrine carcinoma (SNEC)sinonasal undifferentiated carcinoma (SNUC)SOX2βIII-tubulin

Identifiers

PMID37888115
PMCPMC10608336
OpenAlexW4387744510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.